menu search

RYZB / RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range

RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range
RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offering priced at the top end of the expected range. The company said it offered 17.28 million shares in the IPO, up from previous expectations of 14.4 million shares, to raise $311.0 million. Read More
Posted: Sep 15 2023, 06:37
Author Name: Market Watch
Views: 112537

RYZB News  

RayzeBio: Initiating Coverage With Buy Rating And A Price Target Of $43

By Seeking Alpha
October 10, 2023

RayzeBio: Initiating Coverage With Buy Rating And A Price Target Of $43

Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, re more_horizontal

RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion

By Market Watch
September 15, 2023

RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion

Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% abo more_horizontal

RayzeBio to go public at $1B market valuation

By Proactive Investors
September 15, 2023

RayzeBio to go public at $1B market valuation

RayzeBio Inc shares are expected to begin trading on the Nasdaq after Friday's open as the radiopharmaceutical company's upsized initial public offeri more_horizontal

RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range

By Market Watch
September 15, 2023

RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range

RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offer more_horizontal

RayzeBio sets IPO terms, to be valued at up to $1 billion

By Market Watch
September 11, 2023

RayzeBio sets IPO terms, to be valued at up to $1 billion

RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Pha more_horizontal


Search within

Pages Search Results: